Bristol-Myers Squibb Third One fourth Featured Solid Operating Performance Bristol-Myers Squibb Company reported outcomes for the third quarter of 2010. Highlights in the one fourth included: the display of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of essential regulatory milestones in the oncology, immunoscience and diabetes franchises; the acquisition of ZymoGenetics; and double-digit EPS growth sildenafil citrate read more . The business confirmed guidance in 2010 2010. ‘The third quarter continued to highlight the excellent progress we are making with our innovative pipeline, an important driver in the achievement of our differentiated and focused BioPharma strategy,’ said Lamberto Andreotti, ceo, Bristol-Myers Squibb.S., Europe and Japan.

discount viagra

Bristol-Myers Squibb reports outcomes from brivanib as well as sorafenib phase III trial on HCC Bristol-Myers Squibb Company today reported the consequence of the phase III BRISK-FL scientific trial of the investigational agent brivanib versus sorafenib as first-line treatment in sufferers with advanced hepatocellular carcinoma . The scholarly research didn’t meet its primary overall survival objective based on a non-inferiority statistical design. Bristol-Myers Squibb and the lead investigators intend to present the results of the scholarly study at an upcoming scientific meeting.